An Open-label Multicenter Multicohort Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors | NYU Langone Health

Go Back to All Clinical Trials

An Open-label Multicenter Multicohort Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Previouslytreated Locally Advanced Or Metastatic Malignant Solid Tumors
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Subject has measurable disease by RECIST Version 1.1. 2) Subject has accessible archival tumor tissue from either the primary tumor or a metastatic site, for which source and availability have been confirmed prior to study treatment. 3) Subject agrees not to participate in another interventional study while receiving study treatment in the present study.

You may not be eligible for this study if the following are true:

1) Subject has preexisting sensory or motor neuropathy Grade = 2. 2) Subject has active central nervous system (CNS) metastases. 3) Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.